Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
In this phase I-II parallel design, randomized, double-blind clinical trial we will determine
if 3,000 or 30,000 units ingested hrIFN-a prevents deterioration of cognitive functioning in
patients with dementia of Alzheimer's type (AD) and whether ingested hrIFN-a treatment
decreases acute phase reactants and pro-inflammatory cytokine IL-6 in mild to moderate AD. We
predict that the novel anti-inflammatory agent ingested human recombinant interferon alpha
(hrIFN-a) will modulate inflammation and inhibit the natural history of AD progression. If
you are eligible, you will receive Aricept for 5 weeks (donezepil) and thereafter in addition
to Aricept either placebo (inactive substance) or interferon alpha at 3,000 or 30,000 units
every day for 12 months.